Medtronic Announces FDA Approval Of SenSight Directional Lead System For Treating Movement Disorders
Executive Summary
Medtronic said it will launch the SenSight DBS in the US after winning FDA approval. The total DBS market is expected to exceed $1bn by 2024, according to Meddevicetracker.
You may also be interested in...
Medtronic Bounces Back During Quarter Four Of Financial Year 2021 As Procedure Volumes Normalize
Medtronic reported strong growth for the past quarter, with CEO Geoff Martha emphasizing the medtech giant’s efforts in M&A and R&D.
Device Week, 9 June 2021 – ATTD Medtronic Update; CVRx IPO
In this week’s podcast, Medtech Insight's UK-based reporter Barnaby Pickering provides an update on Medtronic’s MiniMed 780G insulin pump cost-savings study, presented at the Advances Technologies & Treatments for Diabetes (ATTD) conference. US Commercial and R&D manager, Reed Miller, highlights details on CVRx’s recent IPO.
Guardant Health, Roche’s Foundation Medicine Receive FDA Companion Diagnostic Nods
Roche’s Foundation Medicine still leads Guardant Health in terms of total companion-diagnostic US FDA approvals as both companies announced new PMA supplements.